Open App
3.5 hours
The Farallon Room at Skyline College
Starting at USD 210
Thu, 05 Jun, 2025 at 05:00 pm to 08:30 pm (GMT-07:00)
The Farallon Room At Skyline College
3300 College Drive, San Bruno, United States
Join us for an exclusive panel featuring academic and industry leaders for an in-depth discussion on the evolving landscape of cell and gene therapies. This panel will span the full innovation arc—from early-stage research and target discovery to clinical translation and commercialization. Panelists will explore the scientific breakthroughs driving the field forward, the persistent challenges in delivery and scalability, and what it will take to bring transformative therapies to patients globally. Whether you're in the lab, clinic, or boardroom, this panel will provide valuable insights into the future of this rapidly advancing field.
Register today to be a part of this interactive panel discussion and to connect with key players, learning their latest strategies, challenges, and vision for the future of cell and gene therapies!
Due to security measures, all attendees must be pre-registered on Eventbrite prior to attending.
Please Note: Everyone attending must have a ticket registered under their own name.
Dr. Urnov is renowned for co-developing the foundational toolbox of human genome and epigenome editing, contributing significantly to the advancement of “genome editing” as a clinical modality. In his work at Sangamo Therapeutics (2000–16), Fyodor and colleagues demonstrated the first use of zinc-finger nucleases to edit DNA in human cell and co-coined the term “genome editing.”
Fyodor was a key member of the team that developed the first-in- human application of genome editing (2009), and then led a cross-functional team from basic discovery to IND of first-in-human clinical trials for the hemoglobinopathies beta-thalassemia and sickle cell disease (trials currently ongoing in partnership with UCSF Benioff Children’s Hospital and UCLA Broad Stem Cell Research Center). At the IGI, Fyodor works in collaborative teams to develop first-in-human applications of experimental CRISPR-based therapeutics for sickle cell disease (with Mark Walters, UCSF), genetic disorders of the immune system (with Alexander Marson, UCSF/IGI), radiation injury (with Jonathan Weissman, MIT/Whitehead Institute), cystic fibrosis (with Ross Wilson, IGI), and neurological disorders (with Weill Neurohub and Roche/Genentech). Currently, he directs the Danaher-IGI Beacon for CRISPR Cures - a first-in-class academia-industry partnership developing and advancing to the clinic scalable CRISPR-based approaches to treat diseases of the immune system. His current projects focus on advancing CRISPR-Cas-based therapeutics for a wide range of genetic, neurodegenerative, and infectious diseases.
Dr. David Miklos is the Chief of Stanford’s BMT and Cell Therapy Program that provides over 700 cancer cell therapies annually. Our allogeneic hematopoietic cell transplantation (alloHCT) research is optimizing graft content of HSC, conventional T lymphocyte, and regulatory T cell content in order to cure blood cancers via beneficial graft-v-tumor (GVT) immunity while reducing GVHD risk. Our CAR-T research provides the most direct targeting of cancer and is dramatically improving leukemia and Lymphoma with no GVHD risk. We are pioneering the combination of graft engineered allogeneic HCT with CAR-T benefit.
The Miklos lab has characterized allogeneic B cells and antibodies after blood transplantation. Our clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. We have developed human correlative assays to optimize CAR-T therapy including ctDNA MRD, tumor antigen quantification, CAR-T immune phenotyping (CAR-FACS), and their single cell RNA and DNA characterization.
Immunotherapy is revolutionizing cancer treatment and Stanford is developing, manufacturing and evaluating the most promising chimeric antigen T-cell (CAR-T) therapies targeting CD19, CD22, B7H3, GD2, and BCMA to benefit patients with cancer and autoimmunity problems.
Pooja Agarwal currently serves as the Head of Therapeutic Modalities and Research
and Early Development Lab Operations at BioMarin, a globally integrated genetic
medicines company dedicated to translating genetic discoveries into transformative
treatments. BioMarin boasts multiple approved medicines that address achondroplasia,
severe hemophilia A, and various rare inherited and lysosomal storage diseases. In her
role, Pooja Agarwal oversees the development of a diverse therapeutic pipeline
featuring best-in-class modalities, including biologics, gene therapies, oligonucleotides,
and small molecules.
Previously, Pooja led the Gene Therapy division at BioMarin for several years. Before
joining BioMarin, she held the position of Senior Vice President of Research and
Development at Krystal Biotech, where she played a pivotal role in the development of
Vyjuvek, the first and only approved redosable topical gene therapy for Recessive
Dystrophic Epidermolysis Bullosa.
Thiago Rampazzo is the Site General Manager at Minaris Regenerative Medicine in Allendale, NJ, a leading CDMO specializing in cell and gene therapies. With extensive experience in pharmaceutical operations, manufacturing, and business leadership, he has been instrumental in driving innovation, operational excellence, and strategic growth across the lifecycle of advanced therapies, from clinical to commercial stages.
Throughout his career, Thiago has led cross-functional teams, overseen large-scale site operations, and navigated complex regulatory landscapes to bring cutting-edge therapies to market. His expertise spans facility management, process optimization, and organizational development, strongly focusing on scalability and quality in cell and gene therapy manufacturing. Thiago’s dedication to continuous learning and his passion for collaboration and leadership allow him to connect effectively with others and drive growth in the industry.
more info at www.bayer.com
more info at https://www.biomerieux.com/
more info at https://bionovascientific.com/
more info at https://www.boehringer-ingelheim.com/
more info at https://www.element.com/
more info at https://www.emerypharma.com/
more info at https://www.eurofins.com/
more info at https://www.gene.com
more info at www.gilead.com
more info at https://globalcompliancepartners.com/
more info at www.nelsonlabs.com
more info at https://www.ntint.com/
more info at www.thermofisher.com
more info at https://www.sterile.com/
How can I contact the organizer with any questions?
You can contact the event organizer by sending an email to cnN2cCB8IHdjY3BkYSAhIG9yZw==. Please allow a few days for the response, emails will not be monitored on the day of the event.
Is my registration fee or ticket transferable?
Tickets are not reimbursable, however you can transfer your ticket by 26MAY25 to whomever would like to attend on your behalf.
My company would like to become a PDA WCC Sponsor, do you have a sponsorship program?
Yes, our offers a unique opportunity for companies that want to strengthen brand image, increase visibility, and gain access to leaders of the San Francisco Bay Life Science Community.
Cancellation & Refund Policy:
Tickets are non-refundable. Seating is confirmed and reserved in advance. All sales are final and no refunds will be provided, including but not limited to non-attendance at the event. If a registrant cannot attend, substitutions are welcome no later than 10 days before the event (26MAY25). The Chapter reserves the right to cancel an event if the minimum number of attendees is not met by the Monday prior to the event. The Chapter reserves the right to not answer emails or phone calls on the day of the event.
Privacy Policy:
We manage your personal data responsibly and align with PDA Privacy Policy.
REGISTRATION AGREEMENT: By registering to this event, I consent to PDA WCC recording and/or photographing me and using those recording(s) and/or photograph(s) in the future PDA WCC promotional and marketing material, and to send me promotional information via email.
Also check out other Business events in San Bruno, Workshops in San Bruno, Nonprofit events in San Bruno.
Tickets for 6th Annual Cell & Gene Therapy Panel can be booked here.
| Ticket type | Ticket price |
|---|---|
| General Admission | 210 USD |
We have gathered all the information for you in one convenient spot, but please keep in mind that these are subject to change.We do our best to keep everything updated, but something might be out of sync. For the latest updates, always check the official event details by clicking the "Find Tickets" button.
Parenteral Drug Association West Coast Chapter
8 Followers
Are you the host? Claim Event
